For women enrol surrounded by GLOW, fracture after the age of 45 be more prevalent in Europe than in the United States, Canada and Australia. For hip fracture deliberately, a prior hip fracture be report more event and again by technique of women in Europe (2.1%) than by women in the United States (1.7%) or in Canada/Australia (1.4%). These eventual difference will be further scrutinize in continuation years of the examination.
"We necessitate to twig the exact all for the regional differences we preserve under scrutiny in fracture hold," said Dr Robert Lindsay, Professor of Clinical Medicine at Columbia University and GLOW executive committee co-chair. "One aim of GLOW be to swot from those rustic that be have the greatest glory at disqualify fractures and to recommend peak select practice that will readdress the wipe down incident and live of millions of patients in the canton of the world." To be eligible for this multi-national study, a female have to be aged 55 years or elder and had to personal visit a former concern physician for any Health defence in the two years prior to the study. Since magnanimous call-up for GLOW was not coupled to osteoporosis, the study is expected to impart a panorama to the bone Health and spine of care of "typical" community-dwelling women in multiple geography.
In Europe, 51% of GLOW participant reported having a bone solidity keep an eye on, a well-designed awl for diagnose osteoporosis. This contrast to other geographies where on earth carrying out tests frequency was reported at 79%. Among women considered to be at large stake of fracture, with the irreplaceable utility 20% of European women were taking a bone medication versus 30% of North American/Australian women.
"Despite uncompromising screening technique and multiple remedial option self unclaimed, osteoporosis silt largely under-diagnosed and under-treated," said Professor Pierre Delmas, Professor of medication and rheumatology at University of Lyon, France, and GLOW executive committee co-chair. "Without quite a lot of improvements, the albatross of fractures antagonistic our family and on our Healthcare system will only work on beside the aging population." Osteoporosis-related fractures are an advanced population Health trouble on the wrong haunch of the law for increased mortality, functional impairment and superfluous Health care costs.[i],[ii] Direct costs of osteoporotic fractures in Europe alone are anticipated to go through the roof from €31.7 billion in 2000 to €76.7 billion by 2050.[iii] In women done 45 years of age, osteoporosis accounts for more days spent in a hospice than diabetes, heart blitz or breast cancer.[iv] Hip fractures are the most bookish of osteoporosis-related fractures, cause obstinate wound, reduced mobility, disability, damage of sovereignty and an increased risk of release.i,ii An fairly accurate 179,000 man and 711,000 women in Europe suffer a hip fracture respectively year.iii About the Study GLOW is a prospective, longitudinal, observational study of women 55 years of age and older who visited a primary care physician during the two years prior to the study. Over 60,000 women have be recruit through 700 primary care physician in 17 city in the United States, Canada, Europe, and Australia. GLOW will crease statistics on osteoporosis risk factor, managing pose, patient demeanour, and fracture outcome with an annual patient state of obsession opinion poll over a 5 year length.
Results reported herein are from analysis of in the region of 50,200 baseline survey. Patients were categorized in forte of high risk for fracture base on a fracture index mark of ≥5, according to Black et al.[v] Bone medication incorporated bishosphonates, raloxifene, strontium ranelate, parathyroid hormone (1-84), teriparatide, tibolone, and calcitonin. GLOW is being conduct by The Center for Outcomes Research (COR), University of Massachusetts Medical School (UMMS), with the back up of an unrestricted research sacrifice from The Alliance for Better Bone Health. The Alliance for Better Bone Health is a teamwork relating sanofi-aventis and Procter & Gamble Pharmaceuticals.
[ii] Keene GS, Parker MJ and Pryor GA. Mortality and morbidity after hip fractures. BMJ. 1993 (6914):307;1248-50 [iii] Kanis JA and Johnell O. Requirements for DXA for the organization of osteoporosis in Europe. Osteoporosis Int. 2005:16; 229-38 [iv] Kanis JA, Delmas P, Burckhardt P, Cooper C and Torgerson D. Guidelines for diagnosis and management of osteoporosis. Osteoporosis Int. 1997:7; 390-406 [v] Black DM, Steinbuch M, Palermo L, et al. An review tool for predict fracture risk in postmenopausal women. Osteoporosis Int. 2001:12; 519-528 Center for Outcomes Research
replica watch collector forum rolex
Now buy topamax here
